FOLH1 and prostate cancer: By conducting cell viability assays in PC-3 and LNCaP cells (Figure 1), the results show non-specific binding with 177Lu on LNCaP cell and 177Lu-PSMA-NARI-56 on PC-3 cell, and we deepen our understanding of how this drug has specific effects on special cells and enhances its therapeutic role due to the albumin in extended prostate cancer treatment.